ALD Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about ALD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 51 trials

Recruiting
Phase 2

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled125 locationsNCT04840602
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled120 locationsNCT05006716
Recruiting
Phase 2

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 2

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
AbbVie14 enrolled2 locationsNCT07387471
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 3

A Long-term Extension Study of PCI-32765 (Ibrutinib)

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled174 locationsNCT01804686
Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma+2 more
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00923507
Recruiting

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Mantle Cell LymphomaSudden Cardiac DeathChronic Lymphocytic Leukemia (CLL)+3 more
National Heart, Lung, and Blood Institute (NHLBI)135 enrolled1 locationNCT05724121
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+5 more
ModeX Therapeutics, An OPKO Health Company180 enrolled1 locationNCT07249905
Recruiting

Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Chronic Lymphocytic LeukemiaHematopoietic and Lymphoid System NeoplasmMantle Cell Lymphoma+2 more
Mayo Clinic100 enrolled1 locationNCT06151730
Recruiting
Phase 1

Study of SGR-1505 in Mature B-Cell Neoplasms

High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting
Phase 1

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+4 more
Newave Pharmaceutical Inc60 enrolled4 locationsNCT04775745
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Follicular Lymphoma ( FL)+3 more
iOMEDICO AG2,950 enrolled1 locationNCT06043011
Recruiting

Steroids-Based Screening for Primary Aldosteronism

HypertensionPrimary Aldosteronism
Qifu Li406 enrolled1 locationNCT06941116
Recruiting
Not Applicable

Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism

Idiopathic HyperaldosteronismHyperaldosteronism
Chinese Academy of Medical Sciences, Fuwai Hospital172 enrolled3 locationsNCT07328230
Recruiting
Phase 1

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaMantle Cell Lymphoma+5 more
Carna Biosciences, Inc.120 enrolled13 locationsNCT05602363
Recruiting
Phase 2

Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

HypercortisolismHyperaldosteronismCushing s Syndrome
National Cancer Institute (NCI)80 enrolled1 locationNCT06246357
Recruiting

Multi-omics Studies of Primary Aldosteronism

Primary Aldosteronism
Peking University First Hospital400 enrolled1 locationNCT07111351
Recruiting
Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

Lymphoplasmacytic LymphomaWaldenström MacroglobulinemiaB-Cell Lymphoproliferative Disorder+1 more
Shayna Sarosiek, MD30 enrolled1 locationNCT06986174